Work

A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5627

Authors: Qi Zhou, Xingtao Long, Dong Wang, Li Li, Ke Wang, Yumei Wu, Guixiang Weng, Tao Wu, Yang Sun, Qingshui Li, Ying Yang, Guiling Li, Weifeng Song, Matko Kalac, Jing Lou

Institutions: Chongqing University, Chongqing Cancer Hospital, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Capital Medical University, Beijing Obstetrics and Gynecology Hospital, Linyi People's Hospital, The First People's Hospital of Changde, Fujian Provincial Cancer Hospital, Shandong Tumor Hospital, Shandong First Medical University, Yuhuangding Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Pfizer (United States)

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162500189

Cites:

Cited by:

Related to: